Assessing the treatment effect in a randomized controlled trial with extensive non-adherence: The EVOLVE trial

Pharmaceutical Statistics

Volumn 14, Issue 3, 2015, Pages 242-251

  Kubo, Yumi ^a   Sterling, Lulu Ren ^a   Parfrey, Patrick S ^b   Gill, Karminder ^c   Mahaffey, Kenneth W ^d   Gioni, Ioanna ^e   Trotman, Marie Louise ^a   Dehmel, Bastian ^a   Chertow, Glenn M ^d  

^a AMGEN INC   (United States)

^b Health Sciences Centre St John's   (Canada)

^c Ascentiant International   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e AMGEN LTD   (United Kingdom)

Author keywords

intention to treat; inverse probability of censoring weights; iterative parameter estimation; lag censoring; non adherence; rank preserving structural failure time model

Indexed keywords

CINACALCET; PLACEBO; CALCIMIMETIC AGENT; HEMODIALYSIS FLUID;

ADULT; ARTICLE; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; FEMALE; FOLLOW UP; HEMODIALYSIS; HUMAN; INTENTION TO TREAT ANALYSIS; INTERVENTION STUDY; MAJOR CLINICAL STUDY; MALE; MORTALITY; OUTCOME ASSESSMENT; RANDOMIZED CONTROLLED TRIAL; SECONDARY HYPERPARATHYROIDISM; AGED; CARDIOVASCULAR DISEASES; CLINICAL TRIAL; HYPERPARATHYROIDISM, SECONDARY; MEDICATION COMPLIANCE; MIDDLE AGED; MULTICENTER STUDY; PROBABILITY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); STANDARDS; STATISTICAL ANALYSIS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; TIME FACTOR; TREATMENT OUTCOME;

AGED; CALCIMIMETIC AGENTS; CARDIOVASCULAR DISEASES; CINACALCET HYDROCHLORIDE; DATA INTERPRETATION, STATISTICAL; DOUBLE-BLIND METHOD; FEMALE; HEMODIALYSIS SOLUTIONS; HUMANS; HYPERPARATHYROIDISM, SECONDARY; INTENTION TO TREAT ANALYSIS; LOGISTIC MODELS; MALE; MEDICATION ADHERENCE; MIDDLE AGED; PROBABILITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TIME FACTORS; TREATMENT OUTCOME;

EID: 84929130655     PISSN: 15391604     EISSN: 15391612     Source Type: Journal    
DOI: 10.1002/pst.1680     Document Type: Article

References (31)

1. Sheiner LB, Rubin DB,. Intention-to-treat analysis and the goals of clinical trials. Clinical Pharmacology and Therapeutics 1995; 57: 6-15.
2. Chertow GM, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS,. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. The New England Journal of Medicine 2012; 367: 2482-94.
3. Chertow GM, Pupim LB, Block GA, Correa-Rotter R, Drueke TB, Floege J, Goodman WG, London GM, Mahaffey KW, Moe SM, Wheeler DC, Albizem M, Olson K, Klassen P, Parfrey P,. Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clinical Journal of the American Society of Nephrology: CJASN 2007; 2: 898-905.
4. Chertow GM, Correa-Rotter R, Block GA, Drueke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Wheeler DC, Parfrey PS,. Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association-European Renal Association 2012; 27: 2872-9.
5. Schulz KF, Altman DG, Moher D,. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMJ; 2010: 340.
6. Gupta SK,. Intention-to-treat concept: a review. Perspectives in Clinical Research 2011; 2: 109-12.
7. Block GA, Spiegel DM, Ehrlich J, Mehta R, Lindbergh J, Dreisbach A, Raggi P,. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney International 2005; 68: 1815-24.
8. Chertow GM, Burke SK, Raggi P,. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney International 2002; 62: 245-52.
9. Raggi P, Chertow GM, Torres PU, Csiky B, Naso A, Nossuli K, Moustafa M, Goodman WG, Lopez N, Downey G, Dehmel B, Floege J;ADVANCEStudyGroup,. The ADVANCE study: a randomized study to evaluate the effects of cinacalcet plus low-dose vitamin D on vascular calcification in patients on hemodialysis. Nephrology, Dialysis, Transplantation: Official Publication of the European Dialysis and Transplant Association-European Renal Association 2011; 26: 1327-39.
10. Robins JM, Finkelstein DM,. Correcting for noncompliance and dependent censoring in an AIDS Clinical Trial with inverse probability of censoring weighted (IPCW) log-rank tests. Biometrics 2000; 56: 779-88.
11. Hernan MA, Brumback B, Robins JM,. Marginal structural models to estimate the causal effect of zidovudine on the survival of HIV-positive men. Epidemiology (Cambridge, Mass) 2000; 11: 561-70.
12. Robins JM, Hernan MA, Brumback B,. Marginal structural models and causal inference in epidemiology. Epidemiology (Cambridge, Mass) 2000; 11: 550-60.
13. Brookhart MA, Schneeweiss S, Rothman KJ, Glynn RJ, Avorn J, Sturmer T,. Variable selection for propensity score models. American Journal of Epidemiology 2006; 163: 1149-56.
14. Howe CJ, Cole SR, Chmiel JS, Munoz A,. Limitation of inverse probability-of-censoring weights in estimating survival in the presence of strong selection bias. American Journal of Epidemiology 2011; 173: 569-77.
15. D'Agostino RB, Lee ML, Belanger AJ, Cupples LA, Anderson K, Kannel WB,. Relation of pooled logistic regression to time dependent Cox regression analysis: the Framingham Heart Study. Statistics in Medicine 1990; 9: 1501-15.
16. Robins JM, Tsiatis AA,. Correcting for non-compliance in randomized trials using rank preserving structural failure time models. Communications in Statistics-Theory and Methods 1991; 20: 2609-31.
17. Kleinbaum DG,. Survival Analysis, a Self-Learning Text. Biometrical Journal 1998; 40: 107-8.
18. Morden JP, Lambert PC, Latimer N, Abrams KR, Wailoo AJ,. Assessing methods for dealing with treatment switching in randomised controlled trials: a simulation study. BMC Medical Research Methodology 2011; 11: 4.
19. White IR, Babiker AG, Walker S, Darbyshire JH,. Randomization-based methods for correcting for treatment changes: examples from the Concorde trial. Statistics in Medicine 1999; 18: 2617-34.
20. Greenland S, Lanes S, Jara M,. Estimating effects from randomized trials with discontinuations: the need for intent-to-treat design and G-estimation. Clinical Trials 2008; 5: 5-13.
21. Branson M, Whitehead J,. Estimating a treatment effect in survival studies in which patients switch treatment. Statistics in Medicine 2002; 21: 2449-63.
22. ®: A Practical Guide, Second Edition. SAS Institute Inc.: Cary, NC, 2010.
23. White I,. Estimating treatment effects in randomized trials with treatment switching [Letter to the Editor]. Statistics in Medicine 2006; 25: 1619-22.
24. International conference on harmonisation, guideline for statistical principles for clinical trials, 1998.
25. Snapinn SM, Jiang Q, Iglewicz B,. Informative noncompliance in endpoint trials. Current Controlled Trials in Cardiovascular Medicine 2004; 5: 5.
26. Lee YJ, Ellenberg JH, Hirtz DG, Nelson KB,. Analysis of clinical trials by treatment actually received: is it really an option ? Statistics in Medicine 1991; 10: 1595-605.
27. Cain LE, Cole SR,. Inverse probability-of-censoring weights for the correction of time-varying noncompliance in the effect of randomized highly active antiretroviral therapy on incident AIDS or death. Statistics in Medicine 2009; 28: 1725-38.
28. Yoshida M, Matsuyama Y, Ohashi Y,. Estimation of treatment effect adjusting for dependent censoring using the IPCW method: an application to a large primary prevention study for coronary events (MEGA study). Clinical Trials (London, England) 2007; 4: 318-28.
29. NICE. Everolimus for the second-line treatment of advanced renal cell carcinoma, 2011. Available from: https://www.nice.org.uk/guidance/ta219/chapter/3-the-manufacturers-submission (accessed 2014 Dec 11).
30. Cole SR, Hernan MA,. Constructing inverse probability weights for marginal structural models. American Journal of Epidemiology 2008; 168: 656-64.
31. Harrell F,. Macro procedure daspline, 2013. Available from: http://www.public.iastate.edu//~textasciitildekkoehler/stat565/sas/daspline.macro.sas (1986, accessed 2013 Nov 05).